About mbiomics
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary microbiome profiling technology at hand, mbiomics is uniquely positioned to understand microbiome modulation and to design effective microbiome therapies.
Press releases
Press
Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round
Munich, Germany, 23 March 2023 – mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors.
mbiomics uses its proprietary, tailored high-resolution profiling platform and computat
![](https://www.htgf.de/wp-content/uploads/2023/03/MBIOMICS_Logo_Orange_CMYK_Big-1-600x156.jpg)
Info & Contact
- E–Mail:
- info@mbiomics.com
- Web:
- mbiomics.com
Address
Kistlerhofstr. 70
Building 79
81379 Munich, Germany
Building 79
81379 Munich, Germany
In portfolio
23. Mar 2023
Sector
Dr. Jan Engels
Investment Manager